Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma

BJU International

Volumn 109, Issue 11, 2012, Pages 1600-1606

  Shuch, Brian ^a,b   Bratslavsky, Gennady ^a   Shih, Joanna ^a   Vourganti, Srinivas ^a   Finley, David ^b   Castor, Brandon ^b   Treat, Eric ^b   Linehan, W Marston ^a   Pantuck, Allan J ^b   Said, Jonathan W ^b   Belldegrun, Arie S ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adjuvant; kidney cancer; prognosis; RCC; sarcomatoid

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER SIZE; CANCER STAGING; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY NECROSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SARCOMATOID CARCINOMA; SARCOMATOID RENAL CELL CARCINOMA; STUDY DESIGN; SURVIVAL TIME; TREATMENT RESPONSE;

AGED; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; SURVIVAL RATE;

EID: 84860617646     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10785.x     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ,. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66 (Pubitemid 46148091)
2. Storkel S, Eble JN, Adlakha K, et al,. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 987-9
3. Kovacs G, Akhtar M, Beckwith BJ, et al,. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183: 131-3
4. Delahunt B,. Sarcomatoid renal carcinoma: the final common dedifferentiation pathway of renal epithelial malignancies. Pathology 1999; 31: 185-90 (Pubitemid 29417595)
5. Cheville JC, Lohse CM, Zincke H, et al,. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 2004; 28: 435-41 (Pubitemid 38436516)
6. Shuch B, Said J, La Rochelle JC, et al,. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology-is up-front resection indicated and, if not, is it avoidable? J Urol 2009; 182: 2164-71
7. Golshayan AR, George S, Heng DY, et al,. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009; 27: 235-41
8. Staehler M, Haseke N, Roosen A, et al,. Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res 2010; 15: 287-91
9. Tomic D, Wood LS, Gallager E, Rini BI,. Metastatic Sarcomatoid Renal Cell Carcinoma Treated With mTOR-Targeted Therapy. Kindey Cancer Symposium; 2010; Chicago, IL, 2010
10. Shuch B, Said J, LaRochelle JC, et al,. Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer 2010; 116: 616-24
11. de Peralta-Venturina M, Moch H, Amin M, et al,. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001; 25: 275-84 (Pubitemid 32174196)
12. Eble J, Sauter G, Epstein J, Sesterhenn I,. Pathology and Genetics, Tumors of the Urinary System and Male Genital Organs. Lyon, France: World Health Organization, International Agency for Research on Cancer, 2004
13. Margulis V, Matin SF, Tannir N, et al,. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008; 180: 94-8
14. Heng DY, Xie W, Regan MM, et al,. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-9
15. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J,. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-40 (Pubitemid 29368255)
16. Ro JY, Ayala AG, Sella A, Samuels ML, Swanson DA,. Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases. Cancer 1987; 59: 516-26 (Pubitemid 17002432)
17. Bertoni F, Ferri C, Benati A, Bacchini P, Corrado F,. Sarcomatoid carcinoma of the kidney. J Urol 1987; 137: 25-8 (Pubitemid 17214216)
18. Haas N, Manola J, Pins M, et al,. ECOG 8802: phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features. ASCO: GU Cancer Symposium 2009. 2009: Abstract 285
19. Goncalves PD, Srougi M, Dall'lio MF, Leite KR, Ortiz V, Hering F,. Low clinical stage renal cell carcinoma: relevance of microvascular tumor invasion as a prognostic variable. J Urol 2004; 172: 470-4 (Pubitemid 38900179)
20. Van Poppel H, Vandendriessche H, Boel K, et al,. Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma. J Urol 1997; 158: 45-9 (Pubitemid 27251591)
21. Shuch B, Pantuck AJ, Pouliot F, et al,. Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance. BJU Int 2011; 108: 343-8
22. Amin MB, Amin MB, Tamboli P, et al,. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002; 26: 281-91 (Pubitemid 34184451)
23. Patard JJ, Leray E, Rioux-Leclercq N, et al,. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23: 2763-71 (Pubitemid 46179466)
24. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML,. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003; 27: 612-24 (Pubitemid 36514472)
25. Tickoo SK, Alden D, Olgac S, et al,. Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol 2007; 177: 1258-63 (Pubitemid 46436019)
26. Sorbellini M, Kattan MW, Snyder ME, et al,. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005; 173: 48-51 (Pubitemid 39627669)
27. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H,. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168: 2395-400 (Pubitemid 35402623)
28. Mian BM, Bhadkamkar N, Slaton JW, et al,. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002; 167: 65-70 (Pubitemid 34024501)